Phaseline

Companies › GV20 Therapeutics

GV20 Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 4 registered trials: 4 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
GV20-0251–Phase 1Solid Tumor, Adult; Solid Tumor Cancer; Head and Neck Squamous Cell Carcinoma HNSCC; HCC - Hepatocellular CarcinomaDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05669430GV20-0251Phase 1Solid Tumor, AdultOncologyDec 2026
NCT07457281GV20-0251Phase 1Head and Neck Squamous Cell Carcinoma HNSCCOncologyApr 2027
NCT07106827GV20-0251Phase 1HCC - Hepatocellular CarcinomaOncologyJun 2027
NCT07070518GV20-0251Phase 1Solid Tumor CancerOncologyJul 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.